Price$156.81+0.05 (+0.03%)
01:30 PM07:45 PM
News · 26 weeks85+45%
2026-01-182026-07-12
Mix3890d
- Insider27(71%)
- SEC Filings4(11%)
- Other4(11%)
- Earnings2(5%)
- Analyst1(3%)
Latest news
25 items- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,550,000 worth of shares (10,000 units at $155.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,500,000 worth of shares (10,000 units at $150.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $99,567 worth of shares (716 units at $139.06) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 87,634 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Conference Call and Webcast Scheduled for 1:30 p.m. PTGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (Internat
- ANALYSTH.C. Wainwright initiated coverage on Glaukos with a new price targetH.C. Wainwright initiated coverage of Glaukos with a rating of Buy and set a new price target of $168.00
- INSIDERCHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 6% to 68,967 units (SEC Form 4) to satisfy withholding obligation4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERPRESIDENT & COO Gilliam Joseph E covered exercise/tax liability with 1,056 shares, decreasing direct ownership by 1% to 72,363 units (SEC Form 4) to satisfy withholding tax4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas covered exercise/tax liability with 483 shares, decreasing direct ownership by 0.54% to 88,350 units (SEC Form 4) to satisfy withholding tax4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex BlepharitisGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos’ proprietary iLution platform, a novel ophthalmic drug-delivery system utilizing patented, cream-based drug formulations applied to the outer surface of the eyelids to enable dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. The platform is designed to
- INSIDERAmendment: SEC Form 4 filed by Director Foley Mark J4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Wen Leana4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Stapley Marc4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Weisner Aimee S4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Kliman Gilbert H4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Hoffmeister David F4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Torres Denice4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $200,855 worth of shares (1,537 units at $130.68) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 88,833 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- SECGlaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - GLAUKOS Corp (0001192448) (Filer)
- INSIDERDirector Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
GKOS FAQ
7 questionsWhat does Glaukos Corporation do?
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure...Where does GKOS stock trade?
Glaukos Corporation (GKOS) is listed on NYSE.What sector and industry is GKOS in?
Glaukos Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Glaukos Corporation go public?
Glaukos Corporation (GKOS) completed its IPO in 2015.What are analysts saying about GKOS?
Glaukos Corporation has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-07-06.What companies are similar to GKOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare GKOS side-by-side with any of them on Quantisnow.How can I track GKOS on Quantisnow?
Quantisnow aggregates Glaukos Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GKOS to receive live email and push alerts on every new disclosure.